Literature DB >> 15307958

The costs of treating external genital warts in England and Wales: a treatment pattern analysis.

Paul C Langley1, David J White, Susan M Drake.   

Abstract

The objective of the study was to determine the cost implications of patterns of treatment for patients with external genital warts. A retrospective case note review was carried out at six genitourinary medicine (GUM) clinics in the UK. Significant variations in the total costs of care were observed across the clinics and across the choice of therapy. The cost per successful outcome was pound 221.81 for males and pound 211.07 for females. A minority of patients accounted for the majority of costs, for example the 30.1% of male patients who recorded six or more visits contributed 66.2% of the total cost. Costs also varied significantly by therapy sequence chosen. Patients who remained on their initial therapy experienced the lowest costs, with the extent to which patients shifted therapies substantially impacting on costs. Therapy sequences involving podophyllin were found to be the most expensive options in achieving a completed episode of care. We concluded that a high proportion of costs for GUM clinics is due to the failure of the initial therapy and by subsequent therapy switching. A greater emphasis on the selection of alternative treatment options, such as the patient-applied therapies, may help to reduce overall costs of care.

Entities:  

Mesh:

Year:  2004        PMID: 15307958     DOI: 10.1258/0956462041558168

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  9 in total

Review 1.  Economic and humanistic burden of external genital warts.

Authors:  Adam J N Raymakers; Mohsen Sadatsafavi; Fawziah Marra; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

2.  An economic model of school-based behavioral interventions to prevent sexually transmitted infections.

Authors:  Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price
Journal:  Int J Technol Assess Health Care       Date:  2012-09-21       Impact factor: 2.188

3.  Incidence of genital warts among the Hong Kong general adult population.

Authors:  Chunqing Lin; Joseph T F Lau; King-Man Ho; Man-Chun Lau; Hi-Yi Tsui; Kuen-Kong Lo
Journal:  BMC Infect Dis       Date:  2010-09-17       Impact factor: 3.090

4.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

5.  The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.

Authors:  S C Woodhall; M Jit; K Soldan; G Kinghorn; R Gilson; M Nathan; J D Ross; C J N Lacey
Journal:  Sex Transm Infect       Date:  2011-06-02       Impact factor: 3.519

6.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

Authors:  Elmar A Joura; Suzanne M Garland; Jorma Paavonen; Daron G Ferris; Gonzalo Perez; Kevin A Ault; Warner K Huh; Heather L Sings; Margaret K James; Richard M Haupt
Journal:  BMJ       Date:  2012-03-27

Review 7.  HPV related diseases in males: a heavy vaccine-preventable burden.

Authors:  P Canepa; A Orsi; M Martini; G Icardi
Journal:  J Prev Med Hyg       Date:  2013-06

8.  Economic evaluation of human papillomavirus vaccination in the United Kingdom.

Authors:  Mark Jit; Yoon Hong Choi; W John Edmunds
Journal:  BMJ       Date:  2008-07-17

9.  A retrospective analysis of the costs and management of genital warts in Italy.

Authors:  Maria Michela Gianino; Sergio Delmonte; Emanuela Lovato; Morena Martinese; Sabrina Rondoletti; Maria Grazia Bernengo; Carla Maria Zotti
Journal:  BMC Infect Dis       Date:  2013-10-09       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.